Introduction

The State of Delaware’s Division of Medicaid and Medical Assistance (DMMA) is seeking feedback on the design and development of a potential Medicaid Office-Based Opioid Treatment (OBOT) program. OBOT is a delivery model which seeks to make medications for opioid use disorder, particularly buprenorphine, widely available in general medical settings. This survey is designed to solicit feedback specifically from provider organizations that would potentially serve as OBOTs in Delaware.

The OBOT concept paper provides a general overview of the proposed design for DMMA’s OBOT program, including eligible provider types; eligible patients; service array and delivery approach; payment model; staffing requirements; performance measures; application and enrollment process; technical assistance; and alignment with other related Delaware initiatives. Prior to completing this survey, please review the draft OBOT Concept paper, which is available at this link.

In addition to soliciting feedback from potential OBOTs via this brief survey instrument, DMMA also released a more comprehensive collaborating entity survey to solicit detailed feedback from a wide range of stakeholders, including but not limited to:
  • Current and potential OBOTs
  • Other health care providers, including those working in hospitals, emergency departments, and specialty behavioral health facilities
  • Pharmacists
  • Beneficiaries and their families
  • State agencies
  • Managed care organizations (MCOs)
  • Community-based organizations and social service providers, including emergency medical services (EMS) and justice partners
Current and potential OBOTs may choose to respond to the OBOT provider survey, the collaborating entity survey, or both.

For any questions or additional comments about the potential Delaware Medicaid OBOT program, please contact SUPPORTAct@delaware.gov.

T